Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: A pilot study

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 68, Issue 1, 2013, Pages 118-124

  Reshef, A ^a   Moldovan, D ^b   Obtulowicz, K ^c   Leibovich, I ^a   Mihaly, E ^d   Visscher, S ^e   Relan, A ^e  

^a SHEBA MEDICAL CENTER   (Israel)

^b UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d Mures County Hospital   (Romania)

^e Pharming Group NV   (Netherlands)

Author keywords

hereditary angioedema; prophylaxis; recombinant human C1 inhibitor

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR;

ADULT; ANGIONEUROTIC EDEMA; ANXIETY; ARTICLE; CLINICAL ARTICLE; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; TREATMENT OUTCOME; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; COMPLEMENT C1 INHIBITOR PROTEIN; FEMALE; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870589984     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12060     Document Type: Article

References (29)

1. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, et al. International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24.
2. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-157.
3. Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M,. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 2011; 66: 192-196.
4. Sheffer AL, Fearon DT, Austen KF,. Hereditary angioedema: a decade of management with stanozolol. J Allergy Clin Immunol 1987; 80: 855-860.
5. Cicardi M, Bergamaschini L, Cugno M, Hack E, Agostoni G, Agostoni A,. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol 1991; 87: 768-773.
6. Bork K, Bygum A, Hardt J,. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008; 100: 153-161.
7. Bork K, Hardt J,. Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int Arch Allergy Immunol 2011; 154: 81-88.
8. Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363: 513-522 e14.
9. van Doorn MB, Burggraaf J, van Dam T, Eerenberg A, Levi M, Hack CE, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005; 116: 876-883.
10. Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, et al. Recombinant human C1 inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126: 821-827.
11. Moldovan D, Reshef A, Fabiani J, Kivity S, Toubi E, Shlesinger M, et al. Efficacy and safety of recombinant human C1 inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy 2012; 000: 929-935.
12. Zilberberg MD, Nathanson BH, Jacobsen T, Tillotson G,. Descriptive epidemiology of hereditary angioedema hospitalizations in the United States, 2004-2007. Allergy Asthma Proc 2011; 32: 248-254.
13. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT,. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010; 31: 407-414.
14. Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114 (3 Suppl): S51-S131.
15. Longhurst HJ, Farkas H, Craig T, Aygoren-Pursun E, Bethune C, Bjorkander J, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010; 6: 22.
16. Levi M, Choi G, Picavet C, Hack CE,. Self-administration of C1 inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2006; 117: 904-908.
17. Waytes AT, Rosen FS, Frank MM,. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334: 1630-1634.
18. Bork K, Witzke G,. Long-term prophylaxis with C1 inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1 inhibitor deficiency. J Allergy Clin Immunol 1989; 83: 677-682.
19. Spath PJ, Wuthrich B, Butler R,. Quantification of C1 inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema-evidence of a functionally critical level of C1 inhibitor concentration. Complement 1984; 1: 147-159.
20. Gelfand JA, Sherins RJ, Alling DW, Frank MM,. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976; 295: 1444-1448.
21. Cocchio C, Marzella N,. Cinryze a human plasma-derived C1 esterase inhibitor for prophylaxis of hereditary angioedema. P T 2009; 34: 293-328.
22. Maplethorpe C,. CINRYZE (C1 Inhibitor) for routine prophylaxis against HAE attacks. [FDA Briefing document] 2008; Available from: http://www.fda.gov/ downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/ LicensedProductsBLAs/FractionatedPlasmaProducts/ucm094092.pdf.
23. Hack CE, Relan A, van Amersfoort ES, Cicardi M,. Target levels of functional C1 inhibitor in hereditary angioedema. Allergy 2012; 67: 123-130.
24. Choi G, Soeters MR, Farkas H, Varga L, Obtulowicz K, Bilo B, et al. Recombinant human C1 inhibitor in the treatment of acute angioedema attacks. Transfusion 2007; 47: 1028-1032.
25. Hack CE, Mannesse M, Baboeram A, Oortwijn B, Relan A,. Immunogenicity assessment of recombinant human C1 inhibitor: an integrated analysis of clinical studies. BioDrugs 2012; 26: 303-313.
26. Bygum A, Andersen KE, Mikkelsen CS,. Self-administration of intravenous C1 inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009; 19: 147-151.
27. Aygören-Pürsün E, Martinez-Saguer I, Rusicke E, Klingebiel T, Kreuz W,. On demand treatment and home therapy of hereditary angioedema in Germany-the Frankfurt experience. Allergy Asthma Clin Immunol 2010; 6: 21.
28. Kreuz W, Rusicke E, Martinez-Saguer I, Aygören-Pürsün E, Heller C, Kingebiel T., Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion 2012; 52: 100-107.
29. Longhurst HJ, Carr S, Khair K,. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol 2007; 147: 11-17.